Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enlivex Ltd. (ENLV : NSDQ)

• Company Description    Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company principally in Israel. Its product pipeline includes the Allocetra which is in clinical trial. Enlivex Ltd., formerly known as Enlivex Therapeutics Ltd., is based in Ness Ziona, Israel. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $0.96 Daily Weekly Monthly 20 Day Moving Average: 259,039 shares Shares Outstanding: 17.49 (millions) Market Capitalization: $16.78 (millions) Beta: 1.42 52 Week High: $19.80 52 Week Low: $0.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.22% -42.17% 12 Week -89.71% -89.92% Year To Date -90.90% -91.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 14 Einstein Street - Ness Ziona,L3 7403618 ISR ph: 972-2620-8072 fax: 972-2620-8070 info@enlivex.com http://www.enlivex.com

• General Corporate Information    Officers Oren Hershkovitz - Chief Executive Officer Shai Novik - Executive Chairman Roger Pomerantz - Vice Chairman and Director Shachar Shlosberger - Chief Financial Officer Gili Hart - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M4130Y171 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 09/11/26 Share - Related Items Shares Outstanding: 17.49 Most Recent Split Date: 7.00 (0.07:1) Beta: 1.42 Market Capitalization: $16.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: -12.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - 248.08 ROA 06/30/26 - - 03/31/26 - - 12/31/25 - 206.39 Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 193.24 Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 193.24 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - 122.21 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - 0.02

Powered by Zacks Investment Research ©